PNB Vesper provides potential option to save hospitalised COVID-19 patients globally
PNB Vesper provides potential option to save hospitalised COVID-19 patients globally
12 February 2021 | News
Source credit: Shutterstock
PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020.
The clinical trial was initiated in November 2020 at BJ Government Medical College and Sassoon General Hospital Pune, and Victoria Medical College and Research Institute, Bengaluru. The clinical trial report will now be submitted to DCGI on February 22, 2021.
Kerala firm successfully completes Phase 2 trials of Covid drug
By IANS |
Published on
Thu, Feb 11 2021 22:57 IST |
0 Views
Despite the widespread use of oral contraceptives (OCPs) by women, many are not aware that it may impair their ability to recognise others emotional expressions, which may have serious consequences in interpersonal contexts, suggests a new study.. Image Source: IANS News
Kochi, Feb 11 : PNB Vesper, a leading Kerala-based life sciences company, on Thursday announced that it has successfully completed the Phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on Covid-19 patients.
The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 trial on patients with moderate Covid and on oxygen support in September 2020.